Literature DB >> 33315669

Ring Sclerosis in Prostate Cancer: Circle of Malignancy or Benignity?

Charles Marcus1, Yoram Baum1, Olayinka A Abiodun-Ojo1, Ashesh B Jani2, David M Schuster1.   

Abstract

ABSTRACT: Prostate cancer osteoblastic metastases may have different morphologies, and some of these may overlap with certain benign bone lesions. In this series of 5 prostate cancer patients, we describe bone lesions with central lucency and surrounding peripheral sclerosis and their varying appearances on different imaging modalities. Although prostate cancer metastases are commonly associated with sclerotic lesions, they can also present as osteolytic or lucent lesions, and these lesions should be carefully evaluated. The findings emphasize the importance of correlation with prior imaging, comparing findings on different imaging techniques and follow-up to differentiate benign disease from metastatic disease in these situations.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33315669      PMCID: PMC8026482          DOI: 10.1097/RLU.0000000000003434

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   10.782


  8 in total

1.  68Ga-PSMA Uptake in Fibrous Dysplasia.

Authors:  Maria Lucia Reale; Consuelo Buttigliero; Marcello Tucci; Roberto Giardino; Carlo Poti
Journal:  Clin Nucl Med       Date:  2019-06       Impact factor: 7.794

2.  Fibrous dysplasia mimicking bone metastasis on 68GA-PSMA PET/MRI.

Authors:  Liesbeth De Coster; Raf Sciot; Wouter Everaerts; Olivier Gheysens; Raf Verscuren; Christophe M Deroose; Steven Pans; Koen Van Laere; Karolien E Goffin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-09       Impact factor: 9.236

3.  Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer.

Authors:  Bo Chen; Peng Wei; Homer A Macapinlac; Yang Lu
Journal:  Nucl Med Commun       Date:  2019-09       Impact factor: 1.690

4.  Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti; Shuntaro Oka; Hiroyuki Okudaira; Yusuke Inoue; Jens Sörensen; Rikard Owenius; Peter Choyke; Baris Turkbey; Trond V Bogsrud; Tore Bach-Gansmo; Raghuveer K Halkar; Jonathon A Nye; Oluwaseun A Odewole; Bital Savir-Baruch; Mark M Goodman
Journal:  J Nucl Med       Date:  2014-11-13       Impact factor: 10.057

Review 5.  Fibrous dysplasia.

Authors:  M J Kransdorf; R P Moser; F W Gilkey
Journal:  Radiographics       Date:  1990-05       Impact factor: 5.333

6.  The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.

Authors:  Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Josef Hammer; Wolfgang Loidl; Christian Pirich; Ignac Fogelman; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2009-07-09       Impact factor: 3.488

7.  Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines.

Authors:  Kelsey L Pomykala; Johannes Czernin; Tristan R Grogan; Wesley R Armstrong; John Williams; Jeremie Calais
Journal:  J Nucl Med       Date:  2019-09-20       Impact factor: 11.082

8.  68Ga-PSMA PET/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls.

Authors:  Zohar Keidar; Ronit Gill; Elinor Goshen; Ora Israel; Tima Davidson; Maryna Morgulis; Natalia Pirmisashvili; Simona Ben-Haim
Journal:  Cancer Imaging       Date:  2018-11-01       Impact factor: 3.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.